BRISTOL-MYERS SQUIBB CO

Insider sale: Bristol‑Myers Squibb’s EVP sells 6,249 shares at $64.57—routine divestment, no sign of trouble, just normal liquidity management.

Insider buying at Bristol‑Myers Squibb: Massacesi’s RSU purchase shows long‑term confidence, boosting BMS’s bullish outlook amid merger chatter.

Insider buying at Bristol‑Myers Squibb shows senior executives betting on the company’s pipeline, boosting confidence for long‑term investors.

Insider buying at BMS signals confidence: EVP Shanahan accumulates shares at a discount near a 52‑week high, boosting long‑term upside for investors.

Insider buying of BMS deferred units signals long‑term confidence, boosting shares toward their 52‑week high and supporting the company’s drug‑pipeline outlook.

Insider buying surge at Bristol‑Myers Squibb signals confidence ahead of key product launches, suggesting a potential upside despite a flat share price.